ARIX BIOSCIENCE PLC
the initiation, design and reporting of data from the AUTO1-AL1 trial and
other clinical trials; the development of Autolus' pipeline of next
generation programs, including for solid tumor indications, in collaboration
with its academic partners, including expectations as to the reporting of
data, conduct and timing; the efficacy, safety and therapeutic potential of
AUTO3 and ability for Autolus to obtain a partner for next stages of
clinical development; needs for additional funding and ability to raise
additional capital; Autolus' ability to attract and retain qualified
employees and key personnel; the restructuring program and Autolus' expected
cash savings as a result of the restructuring program and operational
changes. Any forward-looking statements are based on management's current
views and assumptions and involve risks and uncertainties that could cause
actual results, performance or events to differ materially from those
expressed or implied in such statements. These risks and uncertainties
include, but are not limited to, the risks that Autolus' preclinical or
clinical programs do not advance or result in approved products on a timely
or cost effective basis or at all; the results of early clinical trials are
not always being predictive of future results; the cost, timing and results
of clinical trials; that many product candidates do not become approved
drugs on a timely or cost effective basis or at all; the ability to enroll
patients in clinical trials; possible safety and efficacy concerns; and the
impact of the ongoing COVID-19 pandemic on Autolus' business. For a
discussion of other risks and uncertainties, and other important factors,
any of which could cause Autolus' actual results to differ from those
contained in the forward-looking statements, see the section titled "Risk
Factors" in Autolus' Annual Report on Form 20-F filed with the Securities
and Exchange Commission on March 3, 2020, as amended, as well as discussions
of potential risks, uncertainties, and other important factors in Autolus'
subsequent filings with the Securities and Exchange Commission. All
information in this press release is as of the date of the release, and
Autolus undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, or
otherwise, except as required by law.
Contact:
Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
l.crabtree@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com
# # #
ISIN: GB00BD045071
Category Code: MSCU
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be
disclosed under the laws of a Member State
Sequence No.: 90947
EQS News ID: 1158754
End of Announcement EQS News Service
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=0aa558b60551b0e46e7e08df6adea801&application_id=1158754&site_id=vwd&application_name=news
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1158754&site_id=vwd&application_name=news
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=cd12eb0620a26d46b9f25ecaffc53646&application_id=1158754&site_id=vwd&application_name=news(END) Dow Jones Newswires
January 06, 2021 05:00 ET (10:00 GMT)
